What changed
$ZLAB — BUY 📊 | 6 MONTHS THESIS
🎯 latest | Rev $38M | EPS $-0.46 vs $-0.53 🟢
💡 Consensus expectations underappreciate the revenue ramp from newly launched products and the path to breakeven, focusing on historical losses rather than the improving sales trajectory and pipeline optionality.
📉 Reward/risk: 2.5:1
🏢 Business Quality: 6/10 - Commercial-stage biotech with diversified oncology portfolio, strong partnerships, but still unprofitable and reliant on near-term launch success.
📊 Valuation: cheap: EV/Sales 2.5x vs. Chinese biotech comps at 5-7x; reverse DCF implies market prices zero terminal value for pipeline.
🔮 Catalyst: Q2 2024 earnings or pipeline update
💰 Entry: $18.2, stop $14.0, target $30.0
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/ZLAB0619